Locally Advanced Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase I/II Study of Combined Chemotherapy and High Dose, Accelerated Proton Radiation for the Treatment of Locally Advanced Non-Small Cell Lung Carcinoma
The purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00702975 -
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
|
Phase 2 | |
Recruiting |
NCT05339568 -
Patient's Whole Process Follow-up Management(HOPE-1)
|
||
Recruiting |
NCT04749394 -
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
|
Phase 2 | |
Recruiting |
NCT06287320 -
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
|
||
Completed |
NCT01537991 -
ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial
|
N/A | |
Completed |
NCT04648033 -
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
|
Phase 1 | |
Completed |
NCT01059552 -
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Not yet recruiting |
NCT04153734 -
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
|
Phase 2 | |
Completed |
NCT03371550 -
A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
|
Phase 2 | |
Not yet recruiting |
NCT05620199 -
Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy
|
N/A | |
Withdrawn |
NCT05481775 -
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
|
Phase 2 |